Outlook for 2007

Published on 24 October 2007

Net sales will grow slightly from those of 2006. Sales of pharmaceuticals via Orion’s own sales network will grow moderately in Finland and the markets outside Finland will continue showing growth. In-market sales of the Parkinson’s Disease products will continue showing steady, although slower growth than in the previous years. Deliveries to Novartis are anticipated to be slightly higher than in 2006.

Operating profit, excluding non-recurring items, is estimated to grow slightly from 2006, despite increasing investments in marketing and research. Marketing expenses will grow especially due to product launches by Orion’s own European marketing units outside Finland.

Research and development expenditure will be about EUR 95 million, of which pharmaceutical R&D will account for about EUR 90 million. The higher expenditure is mainly caused by the new clinical studies that have been started in 2007.

Capital expenditure will be about EUR 35 million.

Published on 6 August 2007

Net sales will grow slightly from those of 2006. Sales of pharmaceuticals via Orion’s own sales network will grow moderately in Finland and the markets outside Finland will continue showing growth. In-market sales of the entacapone product franchise will continue showing steady, although slower growth than in the previous years. Deliveries to Novartis are anticipated to be at the same level as in 2006, in which they increased considerably, partly because of higher reserve stockpile levels of Novartis.

Operating profit, excluding one-off earnings, is estimated to grow slightly from 2006, despite increasing investments in marketing and pharmaceutical research. Marketing expenses will grow especially due to product launches by Orion’s own European marketing units outside Finland.

Research and development expenditure will be about EUR 95 million, of which pharmaceutical R&D will account for about EUR 90 million. The higher expenditure is mainly caused by the new clinical studies that have been started in 2007.

Capital expenditure will be about EUR 35 million.

Published on 25 April 2007

Net sales will grow somewhat from those of 2006. Sales of pharmaceuticals via Orion’s own marketing organisation are anticipated to start showing moderate growth in Finland and to go on showing growth in the markets outside Finland. In-market sales of the entacapone product franchise will continue showing steady, although slower growth than in the previous years. Deliveries to Novartis are anticipated to be at the same level as in 2006, in which they increased considerably, partly because of higher reserve stockpile levels of Novartis.

Operating profit, one-off earnings excluded, is estimated to grow somewhat from 2006, despite increased investments in marketing and pharmaceutical research. Marketing expenses will grow especially due to investments in product launches by Orion’s own European marketing units outside Finland. The higher R&D expenditure is mainly caused by the new clinical research programmes being started in 2007.

Research and development expenditure will be about EUR 95 million, of which pharmaceutical R&D will account for about EUR 90 million.

Capital expenditure will be about EUR 35 million.

Published on 6 February 2007

Net sales will grow somewhat from those of 2006. Sales of pharmaceuticals via Orion’s own marketing organisation are anticipated to start showing moderate growth in Finland and to go on showing growth in the markets outside Finland. In-market sales of the entacapone product franchise will continue showing steady, although slower growth than in the previous years. Deliveries to Novartis are anticipated to be at the same level as in 2006, in which they increased considerably, partly because of higher reserve stockpile levels of Novartis.

Operating profit, one-off earnings excluded, is estimated to grow somewhat from 2006, despite increased investments in marketing and pharmaceutical research. Marketing expenses will grow especially due to investments in product launches by Orion’s own European marketing units outside Finland. The higher R&D expenditure is mainly caused by the new clinical research programmes being started in 2007.

Research and development expenditure will be about EUR 95 million, of which pharmaceutical R&D will account for about EUR 90 million.

Capital expenditure will be about EUR 35 million.